Gregory Kinney
Concepts (416)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pulmonary Disease, Chronic Obstructive | 59 | 2025 | 953 | 6.270 |
Why?
| Coronary Artery Disease | 28 | 2025 | 676 | 1.950 |
Why?
| Tomography, X-Ray Computed | 43 | 2025 | 2517 | 1.900 |
Why?
| Smoking | 29 | 2025 | 1459 | 1.860 |
Why?
| Smokers | 18 | 2025 | 138 | 1.780 |
Why?
| Diabetes Mellitus, Type 1 | 38 | 2025 | 3626 | 1.610 |
Why?
| Pulmonary Emphysema | 13 | 2025 | 245 | 1.420 |
Why?
| Cannabis | 9 | 2024 | 426 | 1.360 |
Why?
| Forced Expiratory Volume | 26 | 2025 | 511 | 1.250 |
Why?
| Bronchiectasis | 7 | 2023 | 108 | 1.030 |
Why?
| Calcinosis | 17 | 2015 | 230 | 1.010 |
Why?
| Dronabinol | 4 | 2024 | 167 | 0.940 |
Why?
| Lung | 23 | 2025 | 3748 | 0.870 |
Why?
| Respiratory Function Tests | 11 | 2021 | 580 | 0.860 |
Why?
| Hyperlipidemias | 2 | 2023 | 125 | 0.840 |
Why?
| Spirometry | 16 | 2025 | 254 | 0.840 |
Why?
| Diabetic Ketoacidosis | 3 | 2022 | 197 | 0.830 |
Why?
| Cannabinoids | 5 | 2024 | 129 | 0.820 |
Why?
| Marijuana Smoking | 3 | 2022 | 239 | 0.800 |
Why?
| Cardiovascular System | 1 | 2023 | 137 | 0.780 |
Why?
| Disease Progression | 27 | 2025 | 2604 | 0.770 |
Why?
| Middle Aged | 91 | 2025 | 30921 | 0.760 |
Why?
| Cardiovascular Diseases | 7 | 2024 | 2001 | 0.720 |
Why?
| Diabetic Angiopathies | 11 | 2016 | 261 | 0.680 |
Why?
| Volatilization | 1 | 2019 | 52 | 0.660 |
Why?
| Nebulizers and Vaporizers | 1 | 2019 | 81 | 0.640 |
Why?
| Risk Factors | 39 | 2025 | 9737 | 0.630 |
Why?
| Female | 110 | 2025 | 68266 | 0.630 |
Why?
| Diabetes Mellitus, Type 2 | 5 | 2023 | 2433 | 0.620 |
Why?
| Male | 102 | 2025 | 63043 | 0.610 |
Why?
| Humans | 135 | 2025 | 128495 | 0.610 |
Why?
| Aged | 49 | 2025 | 21974 | 0.590 |
Why?
| Coronary Vessels | 7 | 2021 | 236 | 0.560 |
Why?
| Air Pollution | 1 | 2019 | 215 | 0.540 |
Why?
| Marijuana Abuse | 1 | 2019 | 230 | 0.530 |
Why?
| Cohort Studies | 31 | 2025 | 5402 | 0.520 |
Why?
| Vascular Calcification | 5 | 2019 | 107 | 0.500 |
Why?
| Risk Assessment | 9 | 2024 | 3232 | 0.500 |
Why?
| Prospective Studies | 29 | 2025 | 7069 | 0.500 |
Why?
| Arthritis, Rheumatoid | 4 | 2025 | 1088 | 0.490 |
Why?
| Genetic Predisposition to Disease | 11 | 2025 | 2269 | 0.490 |
Why?
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2016 | 23 | 0.490 |
Why?
| Cigarette Smoking | 3 | 2025 | 88 | 0.470 |
Why?
| Adult | 56 | 2025 | 35299 | 0.450 |
Why?
| Genome-Wide Association Study | 9 | 2025 | 1332 | 0.420 |
Why?
| Vital Capacity | 8 | 2025 | 291 | 0.410 |
Why?
| Cannabidiol | 2 | 2024 | 89 | 0.390 |
Why?
| Pulmonary Artery | 5 | 2024 | 1031 | 0.380 |
Why?
| Longitudinal Studies | 10 | 2024 | 2710 | 0.370 |
Why?
| Coronary Disease | 7 | 2010 | 384 | 0.370 |
Why?
| Airway Obstruction | 2 | 2024 | 149 | 0.350 |
Why?
| Atherosclerosis | 4 | 2023 | 403 | 0.350 |
Why?
| Emphysema | 2 | 2023 | 94 | 0.350 |
Why?
| Prevalence | 13 | 2025 | 2553 | 0.350 |
Why?
| Lung Diseases, Interstitial | 3 | 2025 | 592 | 0.330 |
Why?
| Marijuana Use | 3 | 2024 | 189 | 0.310 |
Why?
| Depression | 4 | 2022 | 1292 | 0.310 |
Why?
| Lipoproteins | 3 | 2016 | 171 | 0.310 |
Why?
| Pectoralis Muscles | 3 | 2021 | 17 | 0.310 |
Why?
| Case-Control Studies | 15 | 2025 | 3339 | 0.300 |
Why?
| Albuminuria | 4 | 2016 | 181 | 0.300 |
Why?
| Cross-Sectional Studies | 16 | 2025 | 5045 | 0.300 |
Why?
| Calcium | 7 | 2018 | 1183 | 0.290 |
Why?
| Severity of Illness Index | 15 | 2023 | 2719 | 0.290 |
Why?
| Bronchi | 3 | 2022 | 241 | 0.280 |
Why?
| Prenatal Exposure Delayed Effects | 2 | 2024 | 564 | 0.280 |
Why?
| Metformin | 2 | 2021 | 314 | 0.280 |
Why?
| Young Adult | 15 | 2023 | 12349 | 0.270 |
Why?
| Body Mass Index | 11 | 2024 | 2263 | 0.260 |
Why?
| Predictive Value of Tests | 10 | 2019 | 1938 | 0.260 |
Why?
| Tandem Mass Spectrometry | 2 | 2019 | 456 | 0.260 |
Why?
| Biomarkers | 12 | 2024 | 3893 | 0.250 |
Why?
| Proportional Hazards Models | 6 | 2019 | 1200 | 0.250 |
Why?
| Hypnotics and Sedatives | 2 | 2019 | 157 | 0.250 |
Why?
| Polymorphism, Single Nucleotide | 6 | 2025 | 2064 | 0.250 |
Why?
| United States | 12 | 2024 | 13840 | 0.240 |
Why?
| Quality of Life | 4 | 2021 | 2688 | 0.240 |
Why?
| Cause of Death | 2 | 2018 | 392 | 0.240 |
Why?
| Genomic Structural Variation | 1 | 2025 | 12 | 0.240 |
Why?
| Pulmonary Diffusing Capacity | 3 | 2023 | 74 | 0.240 |
Why?
| Antidepressive Agents | 3 | 2019 | 223 | 0.240 |
Why?
| Plaque, Atherosclerotic | 2 | 2023 | 55 | 0.230 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 198 | 0.230 |
Why?
| Adrenal Insufficiency | 1 | 2025 | 32 | 0.230 |
Why?
| Self Administration | 1 | 2025 | 122 | 0.230 |
Why?
| Receptors, Antigen, B-Cell | 1 | 2025 | 126 | 0.230 |
Why?
| Aged, 80 and over | 10 | 2024 | 7057 | 0.230 |
Why?
| Adrenergic beta-Antagonists | 2 | 2017 | 320 | 0.230 |
Why?
| Renal Insufficiency | 2 | 2016 | 148 | 0.230 |
Why?
| Follow-Up Studies | 11 | 2022 | 4874 | 0.220 |
Why?
| Birth Weight | 2 | 2024 | 499 | 0.220 |
Why?
| Vaping | 1 | 2025 | 53 | 0.220 |
Why?
| C-Peptide | 1 | 2025 | 163 | 0.220 |
Why?
| Symptom Flare Up | 2 | 2021 | 38 | 0.220 |
Why?
| Polysomnography | 1 | 2024 | 161 | 0.210 |
Why?
| Dyspnea | 5 | 2024 | 239 | 0.210 |
Why?
| Logistic Models | 12 | 2017 | 1980 | 0.210 |
Why?
| Fibrinogen | 3 | 2014 | 164 | 0.200 |
Why?
| Artificial Intelligence | 2 | 2023 | 246 | 0.200 |
Why?
| Tomography, Emission-Computed | 1 | 2022 | 66 | 0.200 |
Why?
| Multimorbidity | 1 | 2023 | 46 | 0.200 |
Why?
| Propofol | 2 | 2021 | 52 | 0.200 |
Why?
| Hydrocortisone | 1 | 2025 | 304 | 0.200 |
Why?
| Limit of Detection | 2 | 2019 | 55 | 0.200 |
Why?
| Adiponectin | 4 | 2016 | 234 | 0.200 |
Why?
| Population Health | 1 | 2023 | 45 | 0.200 |
Why?
| Phenotype | 6 | 2025 | 3051 | 0.200 |
Why?
| Umbilical Cord | 2 | 2021 | 84 | 0.190 |
Why?
| Ketosis | 1 | 2022 | 12 | 0.190 |
Why?
| Cystatin C | 3 | 2011 | 65 | 0.190 |
Why?
| Cholesterol | 4 | 2011 | 406 | 0.190 |
Why?
| Epstein-Barr Virus Infections | 1 | 2023 | 93 | 0.190 |
Why?
| Molecular Epidemiology | 2 | 2019 | 63 | 0.190 |
Why?
| Protective Agents | 1 | 2021 | 37 | 0.180 |
Why?
| Sarcopenia | 1 | 2022 | 74 | 0.180 |
Why?
| Models, Genetic | 1 | 2024 | 593 | 0.180 |
Why?
| Hand Strength | 2 | 2022 | 111 | 0.180 |
Why?
| Hallucinogens | 1 | 2023 | 86 | 0.180 |
Why?
| Self Report | 3 | 2021 | 797 | 0.180 |
Why?
| Antirheumatic Agents | 1 | 2023 | 278 | 0.180 |
Why?
| Angiotensin Receptor Antagonists | 1 | 2021 | 89 | 0.180 |
Why?
| Glucocorticoids | 1 | 2025 | 573 | 0.170 |
Why?
| Muscular Atrophy | 1 | 2021 | 79 | 0.170 |
Why?
| C-Reactive Protein | 2 | 2014 | 398 | 0.170 |
Why?
| Hepatitis C | 1 | 2023 | 237 | 0.170 |
Why?
| 2-Propanol | 1 | 2019 | 20 | 0.170 |
Why?
| Pulmonary Heart Disease | 1 | 2019 | 6 | 0.160 |
Why?
| Delirium | 1 | 2021 | 78 | 0.160 |
Why?
| B-Lymphocytes | 1 | 2025 | 814 | 0.160 |
Why?
| Osteoporosis | 1 | 2022 | 233 | 0.160 |
Why?
| Foam Cells | 1 | 2019 | 15 | 0.160 |
Why?
| Hyperostosis | 1 | 2019 | 5 | 0.160 |
Why?
| Genetic Markers | 2 | 2019 | 338 | 0.160 |
Why?
| Calibration | 1 | 2019 | 135 | 0.160 |
Why?
| Diabetic Nephropathies | 2 | 2016 | 279 | 0.160 |
Why?
| Carbon Monoxide | 1 | 2019 | 68 | 0.160 |
Why?
| Spectrometry, Mass, Electrospray Ionization | 1 | 2019 | 167 | 0.160 |
Why?
| Regression Analysis | 6 | 2022 | 982 | 0.160 |
Why?
| Multifactorial Inheritance | 3 | 2025 | 150 | 0.150 |
Why?
| Sleep | 1 | 2024 | 682 | 0.150 |
Why?
| Anti-Anxiety Agents | 1 | 2019 | 42 | 0.150 |
Why?
| Blood Glucose | 6 | 2022 | 2092 | 0.150 |
Why?
| Adipose Tissue | 2 | 2017 | 589 | 0.150 |
Why?
| Surface Properties | 1 | 2019 | 394 | 0.150 |
Why?
| Diabetes Complications | 2 | 2010 | 223 | 0.150 |
Why?
| Drug Overdose | 1 | 2022 | 321 | 0.150 |
Why?
| Heart Ventricles | 2 | 2020 | 767 | 0.150 |
Why?
| Insulin Resistance | 4 | 2017 | 1164 | 0.150 |
Why?
| Diabetes Mellitus, Experimental | 1 | 2019 | 175 | 0.140 |
Why?
| Idiopathic Pulmonary Fibrosis | 1 | 2025 | 623 | 0.140 |
Why?
| Population Surveillance | 1 | 2021 | 435 | 0.140 |
Why?
| Organ Size | 4 | 2021 | 441 | 0.140 |
Why?
| Factor Analysis, Statistical | 1 | 2018 | 283 | 0.140 |
Why?
| Vascular Remodeling | 1 | 2019 | 181 | 0.140 |
Why?
| Sexual and Gender Minorities | 1 | 2021 | 193 | 0.140 |
Why?
| Urine | 1 | 2017 | 56 | 0.140 |
Why?
| Polymorphism, Genetic | 3 | 2011 | 639 | 0.140 |
Why?
| Linear Models | 6 | 2019 | 816 | 0.140 |
Why?
| Environmental Monitoring | 1 | 2019 | 315 | 0.140 |
Why?
| HIV Infections | 2 | 2023 | 2711 | 0.140 |
Why?
| Chronic Disease | 1 | 2023 | 1692 | 0.140 |
Why?
| Lung Diseases | 1 | 2023 | 715 | 0.130 |
Why?
| Growth Differentiation Factor 15 | 1 | 2017 | 39 | 0.130 |
Why?
| Obesity | 4 | 2022 | 2864 | 0.130 |
Why?
| Bronchitis, Chronic | 1 | 2016 | 19 | 0.130 |
Why?
| Prenatal Care | 1 | 2019 | 275 | 0.130 |
Why?
| Blood Pressure | 5 | 2023 | 1712 | 0.130 |
Why?
| Plasma | 1 | 2017 | 200 | 0.130 |
Why?
| Anxiety | 2 | 2022 | 952 | 0.120 |
Why?
| Comorbidity | 5 | 2021 | 1541 | 0.120 |
Why?
| Aortography | 1 | 2015 | 51 | 0.120 |
Why?
| Intraoperative Neurophysiological Monitoring | 1 | 2015 | 21 | 0.120 |
Why?
| Multivariate Analysis | 5 | 2019 | 1499 | 0.120 |
Why?
| Dexmedetomidine | 1 | 2015 | 42 | 0.120 |
Why?
| Respiratory System | 1 | 2016 | 152 | 0.120 |
Why?
| Periodontal Diseases | 1 | 2015 | 62 | 0.120 |
Why?
| Machine Learning | 1 | 2019 | 444 | 0.120 |
Why?
| Endothelium, Vascular | 1 | 2021 | 844 | 0.120 |
Why?
| Adiposity | 2 | 2022 | 504 | 0.110 |
Why?
| Exercise Tolerance | 3 | 2023 | 273 | 0.110 |
Why?
| Evoked Potentials | 1 | 2015 | 116 | 0.110 |
Why?
| Respiratory Muscles | 1 | 2014 | 32 | 0.110 |
Why?
| Evoked Potentials, Somatosensory | 2 | 2015 | 32 | 0.110 |
Why?
| Health Status | 2 | 2022 | 747 | 0.110 |
Why?
| Polycystic Ovary Syndrome | 1 | 2017 | 163 | 0.110 |
Why?
| Body Composition | 4 | 2021 | 644 | 0.110 |
Why?
| Subcutaneous Fat | 1 | 2014 | 74 | 0.110 |
Why?
| Pregnancy Complications | 1 | 2019 | 491 | 0.110 |
Why?
| Heart | 1 | 2017 | 637 | 0.110 |
Why?
| Spine | 1 | 2015 | 156 | 0.110 |
Why?
| Haplotypes | 2 | 2025 | 471 | 0.110 |
Why?
| Up-Regulation | 1 | 2016 | 823 | 0.100 |
Why?
| Sex Distribution | 5 | 2014 | 358 | 0.100 |
Why?
| Aorta | 1 | 2015 | 408 | 0.100 |
Why?
| Orthopedic Procedures | 1 | 2015 | 207 | 0.100 |
Why?
| Incidence | 4 | 2024 | 2638 | 0.100 |
Why?
| Prognosis | 5 | 2024 | 3780 | 0.100 |
Why?
| Colorado | 6 | 2021 | 4399 | 0.100 |
Why?
| Surveys and Questionnaires | 8 | 2025 | 5371 | 0.100 |
Why?
| Time Factors | 7 | 2024 | 6505 | 0.100 |
Why?
| Imaging, Three-Dimensional | 1 | 2015 | 529 | 0.090 |
Why?
| Registries | 1 | 2019 | 1883 | 0.090 |
Why?
| Blood Vessels | 1 | 2013 | 183 | 0.090 |
Why?
| Triglycerides | 2 | 2011 | 523 | 0.090 |
Why?
| Haptoglobins | 1 | 2011 | 52 | 0.090 |
Why?
| Reference Values | 4 | 2023 | 780 | 0.090 |
Why?
| Hypertension, Pulmonary | 1 | 2022 | 1749 | 0.090 |
Why?
| Occupational Exposure | 1 | 2014 | 299 | 0.090 |
Why?
| Genotype | 4 | 2024 | 1830 | 0.090 |
Why?
| Adolescent | 6 | 2022 | 20304 | 0.090 |
Why?
| Carotid Intima-Media Thickness | 2 | 2023 | 90 | 0.080 |
Why?
| Walk Test | 2 | 2021 | 70 | 0.080 |
Why?
| Patient Education as Topic | 2 | 2005 | 734 | 0.080 |
Why?
| Alcohol Drinking | 2 | 2009 | 758 | 0.080 |
Why?
| Diagnostic Techniques, Neurological | 1 | 2009 | 9 | 0.080 |
Why?
| Statistics, Nonparametric | 1 | 2011 | 419 | 0.080 |
Why?
| Coma | 1 | 2009 | 32 | 0.080 |
Why?
| Retrospective Studies | 8 | 2021 | 14471 | 0.080 |
Why?
| Pediatric Obesity | 1 | 2017 | 570 | 0.080 |
Why?
| Pregnancy | 4 | 2024 | 6373 | 0.080 |
Why?
| Facial Nerve | 1 | 2009 | 33 | 0.080 |
Why?
| Monitoring, Intraoperative | 1 | 2009 | 44 | 0.080 |
Why?
| Hypoxia-Ischemia, Brain | 1 | 2009 | 31 | 0.080 |
Why?
| Aortic Diseases | 1 | 2010 | 114 | 0.080 |
Why?
| Lymphatic Abnormalities | 1 | 2009 | 19 | 0.080 |
Why?
| Uric Acid | 1 | 2010 | 160 | 0.080 |
Why?
| Respiratory Physiological Phenomena | 2 | 2022 | 30 | 0.080 |
Why?
| Sensitivity and Specificity | 3 | 2022 | 1817 | 0.080 |
Why?
| Hypertension | 5 | 2015 | 1236 | 0.080 |
Why?
| Reproducibility of Results | 5 | 2017 | 3021 | 0.080 |
Why?
| Kidney | 1 | 2016 | 1310 | 0.080 |
Why?
| Diet, Ketogenic | 1 | 2009 | 35 | 0.080 |
Why?
| Airway Remodeling | 2 | 2021 | 58 | 0.080 |
Why?
| Odds Ratio | 4 | 2014 | 1019 | 0.080 |
Why?
| Asymptomatic Diseases | 2 | 2021 | 84 | 0.080 |
Why?
| Anesthesia, Intravenous | 2 | 2021 | 11 | 0.080 |
Why?
| Proteinuria | 1 | 2009 | 88 | 0.080 |
Why?
| Aorta, Thoracic | 1 | 2010 | 260 | 0.070 |
Why?
| Reproductive History | 1 | 2008 | 18 | 0.070 |
Why?
| Sex Factors | 4 | 2020 | 1951 | 0.070 |
Why?
| Coronary Angiography | 2 | 2014 | 306 | 0.070 |
Why?
| Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| Face | 1 | 2009 | 165 | 0.070 |
Why?
| Radiography | 3 | 2016 | 795 | 0.070 |
Why?
| Cystatins | 1 | 2007 | 6 | 0.070 |
Why?
| Asthma | 1 | 2021 | 2213 | 0.070 |
Why?
| Age of Onset | 2 | 2025 | 495 | 0.070 |
Why?
| Inflammation | 2 | 2021 | 2666 | 0.070 |
Why?
| Life Style | 1 | 2009 | 459 | 0.070 |
Why?
| Dietary Fats | 1 | 2009 | 301 | 0.070 |
Why?
| Kidney Diseases | 1 | 2010 | 370 | 0.070 |
Why?
| Heart Rate | 1 | 2010 | 798 | 0.070 |
Why?
| Mortality | 2 | 2019 | 306 | 0.070 |
Why?
| Renin-Angiotensin System | 1 | 2007 | 79 | 0.070 |
Why?
| Apolipoproteins A | 1 | 2006 | 19 | 0.070 |
Why?
| Apolipoproteins C | 1 | 2006 | 6 | 0.060 |
Why?
| Child, Preschool | 4 | 2024 | 10487 | 0.060 |
Why?
| Contraception | 1 | 2008 | 153 | 0.060 |
Why?
| Propensity Score | 2 | 2019 | 265 | 0.060 |
Why?
| Cluster Analysis | 2 | 2019 | 479 | 0.060 |
Why?
| Receptors, Interleukin-2 | 1 | 2005 | 65 | 0.060 |
Why?
| Internationality | 2 | 2017 | 149 | 0.060 |
Why?
| Receptors, IgG | 1 | 2005 | 74 | 0.060 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 411 | 0.060 |
Why?
| Chi-Square Distribution | 3 | 2010 | 512 | 0.060 |
Why?
| Immunoglobulin Heavy Chains | 1 | 2025 | 80 | 0.060 |
Why?
| Chromosomes, Human, Pair 6 | 1 | 2025 | 51 | 0.060 |
Why?
| Abdominal Wall | 1 | 2004 | 23 | 0.060 |
Why?
| Pandemics | 2 | 2024 | 1477 | 0.060 |
Why?
| Drug Repositioning | 1 | 2024 | 25 | 0.060 |
Why?
| Antihypertensive Agents | 2 | 2007 | 482 | 0.060 |
Why?
| Protein Interaction Maps | 1 | 2024 | 40 | 0.060 |
Why?
| Apolipoprotein C-III | 2 | 2019 | 13 | 0.060 |
Why?
| Whole Genome Sequencing | 1 | 2025 | 130 | 0.060 |
Why?
| United Kingdom | 1 | 2024 | 258 | 0.050 |
Why?
| HLA Antigens | 1 | 2025 | 234 | 0.050 |
Why?
| Glomerular Filtration Rate | 3 | 2016 | 684 | 0.050 |
Why?
| Glucose Clamp Technique | 2 | 2017 | 194 | 0.050 |
Why?
| Cholesterol, LDL | 1 | 2005 | 357 | 0.050 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 372 | 0.050 |
Why?
| Antigens, CD | 1 | 2005 | 482 | 0.050 |
Why?
| Insulin | 3 | 2022 | 2316 | 0.050 |
Why?
| Nutrition Surveys | 1 | 2024 | 261 | 0.050 |
Why?
| Herpesvirus 4, Human | 1 | 2023 | 152 | 0.050 |
Why?
| Blood Platelets | 1 | 2005 | 377 | 0.050 |
Why?
| Morbidity | 1 | 2022 | 301 | 0.050 |
Why?
| Radiography, Thoracic | 2 | 2014 | 164 | 0.050 |
Why?
| Muscles | 1 | 2022 | 322 | 0.050 |
Why?
| Survival Analysis | 2 | 2017 | 1265 | 0.050 |
Why?
| Lung Volume Measurements | 1 | 2021 | 43 | 0.050 |
Why?
| Biological Variation, Population | 1 | 2021 | 20 | 0.050 |
Why?
| Hepacivirus | 1 | 2023 | 235 | 0.050 |
Why?
| Reaction Time | 2 | 2015 | 407 | 0.050 |
Why?
| Protective Factors | 1 | 2021 | 91 | 0.040 |
Why?
| Plethysmography | 1 | 2021 | 107 | 0.040 |
Why?
| Breast Feeding | 1 | 2024 | 422 | 0.040 |
Why?
| Adrenergic beta-2 Receptor Agonists | 1 | 2021 | 35 | 0.040 |
Why?
| Anesthesia, General | 1 | 2021 | 49 | 0.040 |
Why?
| Hospitals, Urban | 1 | 2021 | 129 | 0.040 |
Why?
| Substance Abuse Detection | 1 | 2021 | 74 | 0.040 |
Why?
| Diabetes Mellitus | 1 | 2009 | 996 | 0.040 |
Why?
| Models, Statistical | 1 | 2024 | 622 | 0.040 |
Why?
| Bayes Theorem | 1 | 2022 | 373 | 0.040 |
Why?
| Child Development | 1 | 2024 | 455 | 0.040 |
Why?
| Hospitals, Pediatric | 2 | 2017 | 509 | 0.040 |
Why?
| Homosexuality, Male | 1 | 2021 | 175 | 0.040 |
Why?
| Oligodeoxyribonucleotides, Antisense | 1 | 2019 | 8 | 0.040 |
Why?
| Treatment Outcome | 3 | 2021 | 10162 | 0.040 |
Why?
| Computer Simulation | 1 | 2024 | 939 | 0.040 |
Why?
| Lipids | 2 | 2017 | 621 | 0.040 |
Why?
| rab4 GTP-Binding Proteins | 1 | 2019 | 9 | 0.040 |
Why?
| Cytochrome P-450 CYP2B6 | 1 | 2019 | 9 | 0.040 |
Why?
| Cytochrome P450 Family 2 | 1 | 2019 | 12 | 0.040 |
Why?
| Analysis of Variance | 2 | 2014 | 1273 | 0.040 |
Why?
| Bronchodilator Agents | 1 | 2021 | 243 | 0.040 |
Why?
| Proof of Concept Study | 1 | 2019 | 65 | 0.040 |
Why?
| RNA, Viral | 1 | 2023 | 615 | 0.040 |
Why?
| Administration, Inhalation | 1 | 2021 | 661 | 0.040 |
Why?
| Aryl Hydrocarbon Hydroxylases | 1 | 2019 | 42 | 0.040 |
Why?
| Multidetector Computed Tomography | 1 | 2019 | 33 | 0.040 |
Why?
| Genetic Variation | 1 | 2024 | 935 | 0.040 |
Why?
| Bone Density | 1 | 2022 | 474 | 0.040 |
Why?
| Genomics | 1 | 2023 | 715 | 0.040 |
Why?
| Electroencephalography | 1 | 2021 | 396 | 0.040 |
Why?
| Europe | 1 | 2019 | 360 | 0.040 |
Why?
| Exercise | 1 | 2009 | 1918 | 0.040 |
Why?
| Systems Biology | 1 | 2018 | 59 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2021 | 1016 | 0.040 |
Why?
| Atmospheric Pressure | 1 | 2017 | 15 | 0.040 |
Why?
| Gene Expression Profiling | 1 | 2024 | 1689 | 0.040 |
Why?
| Electrocardiography | 2 | 2010 | 608 | 0.040 |
Why?
| Electric Impedance | 1 | 2017 | 101 | 0.030 |
Why?
| Adrenal Cortex Hormones | 1 | 2021 | 518 | 0.030 |
Why?
| Maternal Health Services | 1 | 2019 | 95 | 0.030 |
Why?
| Total Lung Capacity | 1 | 2016 | 33 | 0.030 |
Why?
| Diagnostic Imaging | 1 | 2019 | 332 | 0.030 |
Why?
| Glucose | 1 | 2022 | 983 | 0.030 |
Why?
| Michigan | 1 | 2017 | 103 | 0.030 |
Why?
| Bronchial Arteries | 1 | 2016 | 12 | 0.030 |
Why?
| Causality | 1 | 2017 | 116 | 0.030 |
Why?
| RNA | 1 | 2023 | 881 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2018 | 856 | 0.030 |
Why?
| Area Under Curve | 1 | 2016 | 293 | 0.030 |
Why?
| Urban Population | 1 | 2019 | 441 | 0.030 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2017 | 488 | 0.030 |
Why?
| Statistics as Topic | 1 | 2016 | 304 | 0.030 |
Why?
| Evoked Potentials, Visual | 1 | 2015 | 35 | 0.030 |
Why?
| Evoked Potentials, Motor | 1 | 2015 | 40 | 0.030 |
Why?
| Anesthetics, Intravenous | 1 | 2015 | 38 | 0.030 |
Why?
| Automation | 1 | 2015 | 80 | 0.030 |
Why?
| Cough | 1 | 2016 | 115 | 0.030 |
Why?
| Cognition | 1 | 2023 | 1110 | 0.030 |
Why?
| Infant | 2 | 2024 | 9001 | 0.030 |
Why?
| ROC Curve | 1 | 2016 | 502 | 0.030 |
Why?
| Muscle Strength | 1 | 2018 | 304 | 0.030 |
Why?
| Physical Endurance | 1 | 2016 | 262 | 0.030 |
Why?
| Sex Characteristics | 2 | 2014 | 722 | 0.030 |
Why?
| Gastroesophageal Reflux | 1 | 2017 | 230 | 0.030 |
Why?
| Stroke | 1 | 2003 | 1073 | 0.030 |
Why?
| Inflammation Mediators | 1 | 2017 | 498 | 0.030 |
Why?
| Piperidines | 1 | 2015 | 191 | 0.030 |
Why?
| Mice | 2 | 2021 | 16620 | 0.030 |
Why?
| Dyslipidemias | 1 | 2015 | 176 | 0.030 |
Why?
| Infant, Newborn | 1 | 2024 | 5740 | 0.030 |
Why?
| Hypercholesterolemia | 1 | 2014 | 101 | 0.030 |
Why?
| Angiography | 1 | 2013 | 192 | 0.020 |
Why?
| Mice, Knockout | 1 | 2019 | 2765 | 0.020 |
Why?
| Quality Improvement | 1 | 2021 | 1097 | 0.020 |
Why?
| Vascular Stiffness | 1 | 2017 | 463 | 0.020 |
Why?
| Child | 2 | 2025 | 20805 | 0.020 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 328 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2021 | 5281 | 0.020 |
Why?
| Exercise Test | 1 | 2014 | 615 | 0.020 |
Why?
| Double-Blind Method | 1 | 2015 | 1856 | 0.020 |
Why?
| Gene Frequency | 1 | 2011 | 504 | 0.020 |
Why?
| Renal Insufficiency, Chronic | 1 | 2016 | 564 | 0.020 |
Why?
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2010 | 99 | 0.020 |
Why?
| Median Nerve | 1 | 2009 | 22 | 0.020 |
Why?
| Facial Paralysis | 1 | 2009 | 17 | 0.020 |
Why?
| Intra-Abdominal Fat | 1 | 2010 | 88 | 0.020 |
Why?
| Artifacts | 1 | 2009 | 123 | 0.020 |
Why?
| Observer Variation | 1 | 2009 | 313 | 0.020 |
Why?
| Personality Inventory | 1 | 2009 | 137 | 0.020 |
Why?
| Animals | 2 | 2021 | 34647 | 0.020 |
Why?
| Chromatography, Liquid | 1 | 2010 | 381 | 0.020 |
Why?
| Age Factors | 2 | 2007 | 3122 | 0.020 |
Why?
| Diabetic Neuropathies | 1 | 2009 | 86 | 0.020 |
Why?
| Algorithms | 1 | 2015 | 1614 | 0.020 |
Why?
| Health Surveys | 1 | 2009 | 493 | 0.020 |
Why?
| Angiotensins | 1 | 2007 | 9 | 0.020 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 21 | 0.020 |
Why?
| Electromyography | 1 | 2009 | 381 | 0.020 |
Why?
| Preoperative Care | 1 | 2009 | 336 | 0.020 |
Why?
| Peptidyl-Dipeptidase A | 1 | 2007 | 50 | 0.020 |
Why?
| Contraceptive Agents, Female | 1 | 2008 | 78 | 0.020 |
Why?
| Diabetic Retinopathy | 1 | 2009 | 172 | 0.020 |
Why?
| Patient Selection | 1 | 2010 | 661 | 0.020 |
Why?
| Self Care | 1 | 2009 | 369 | 0.020 |
Why?
| Amino Acid Substitution | 1 | 2006 | 281 | 0.020 |
Why?
| Waist-Hip Ratio | 1 | 2004 | 35 | 0.010 |
Why?
| Platelet Aggregation | 1 | 2005 | 94 | 0.010 |
Why?
| Radiography, Abdominal | 1 | 2004 | 45 | 0.010 |
Why?
| Hospitalization | 1 | 2014 | 2069 | 0.010 |
Why?
| Age Distribution | 1 | 2005 | 373 | 0.010 |
Why?
| Anthropometry | 1 | 2004 | 204 | 0.010 |
Why?
| Feeding Behavior | 1 | 2009 | 619 | 0.010 |
Why?
| Alleles | 1 | 2006 | 842 | 0.010 |
Why?
| Flow Cytometry | 1 | 2005 | 1142 | 0.010 |
Why?
| Promoter Regions, Genetic | 1 | 2006 | 1199 | 0.010 |
Why?
| Neoplasms | 1 | 2016 | 2463 | 0.010 |
Why?
| Risk | 1 | 2003 | 853 | 0.010 |
Why?
| Hyperglycemia | 1 | 2003 | 326 | 0.010 |
Why?
| Oxidative Stress | 1 | 2006 | 1191 | 0.010 |
Why?
| DNA | 1 | 2006 | 1394 | 0.010 |
Why?
| Postoperative Complications | 1 | 2009 | 2462 | 0.010 |
Why?
| Hypoglycemic Agents | 1 | 2005 | 1217 | 0.010 |
Why?
|
|
Kinney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|